Medical Devices

A new settlement positions a cost-effective alternative to the blockbuster eye drug Eylea for a 2026 U.S. launch, signaling intense market disruption.

Researchers at Kanazawa University have developed engineered nanoparticles that can reprogram rogue immune cells, offering a targeted therapy for autoimmune diseases.

Facing a critical cash shortfall, Cue Biopharma turns to the market, betting its promising cancer and autoimmune pipeline can win over investors.

A new standing wheelchair module offers unprecedented height, blending advanced engineering with profound health and social benefits for users.

As pharma sells GLP-1s directly to patients, doctors are split on the new model. Is it a lifeline for access or a risk to integrated patient care?

A simple, low-cost heart pill may hold the key to treating Alzheimer's and kidney disease. CardioPharma is now funding research to unlock its potential.

Picard Medical rings the NYSE bell, but its stock's volatile journey reflects the high-stakes gamble on its next-generation artificial heart technology.

Johnson & Johnson's TRUFILL n-BCA gains FDA approval for chronic subdural hematoma, offering a minimally invasive option to curb high rates of recurrence.

A breakthrough genetic test helps prostate cancer patients avoid severe side effects from radiation while saving the healthcare system millions of dollars.

With FDA approval for a pivotal study, Pulse Biosciences' novel nanosecond ablation technology aims to make atrial fibrillation treatment safer and more precise.

Molecular Partners readies for a pivotal presentation at the J.P. Morgan conference, showcasing its next-gen DARPin therapeutics for hard-to-treat cancers.

Celltrion's SteQeyma autoinjector gets a CHMP nod, enhancing patient care and intensifying competition in Europe's crowded biosimilar market.

Bolstered by positive clinical data and top investors, Kalaris Therapeutics extends its runway to advance TH103, a next-gen treatment for neovascular AMD.

An international expert panel endorses an advanced wound therapy, potentially revolutionizing patient recovery and boosting a key player in the med-tech market.

Early Phase 1a data for Kalaris's new nAMD drug shows significant vision improvement and potential for extended durability, aiming to reduce patient burden.

Incyte's Minjuvi, a first-of-its-kind immunotherapy, gains EC approval for follicular lymphoma, offering patients a powerful new chemo-free option.

A $100,000 grant empowers a Tennessee non-profit to expand vital dental and medical services to one of the state's most underserved rural counties.

As biotech and pharma risks evolve, Verist Inc. launches tailored coverage, aiming to redefine insurance with a high-touch, data-driven service model.

A Phase 1 trial for Moleculin's WP1066 shows encouraging safety and anti-tumor activity for children with deadly brain tumors like DIPG.

A new once-monthly, self-injected cholesterol drug gets FDA nod, offering more convenience and setting the stage for a major market push in China.